Steven A. Kaplan, MD

Steven A. Kaplan, MD

Icahn School of Medicine at Mount Sinai

New York, New York

Dr. Steven A. Kaplan is the Director of the Men’s Wellness Program at Mount Sinai Health System and a Professor of Urology at the Icahn School of Medicine at Mount Sinai. He is an internationally renowned leader in the study of benign diseases of the prostate, the association of metabolic factors with voiding dysfunction, and female urology.

Dr. Kaplan graduated from Mount Sinai School of Medicine in 1982. Dr. Kaplan’s postgraduate training included an internship and residency in the Department of Surgery at Mount Sinai Hospital, as well as a residency in urology at the Squier Urologic Clinic at Columbia University.

Dr. Kaplan is a Diplomat of the American Board of Urology and a Fellow of the American College of Surgeons. He is a writer on over 1000 publications, and he is also the co-author of five books and is on the editorial boards of numerous journals, including Urology, the Journal of Urology, and the Urology Times. His landmark study, published in JAMA in 2006, changed the way medications are used in the treatment of men with symptoms related to both benign prostate enlargement and bladder dysfunction.

Dr. Kaplan joined Mount Sinai from Weill Cornell Medical College, where he held the tenured position of E. Darracott Vaughan, Jr., Professor of Urology, and also served as Director of the Iris Cantor Men’s Health Center. While at Weill Cornell Medical College, he was actively engaged in teaching and supervising residents and fellows, and was the Director of the Fellowship Program in Male and Female Voiding Dysfunction. He also held the tenured position of Given Foundation Professor of Urology at Columbia University and was the Vice Chairman and Program Director.

Talks by Steven A. Kaplan, MD

Optilume® BPH Catheter System: Optilume® Care Pathway and Treatment Options

Optilume® BPH Catheter System: Optilume® Care Pathway and Treatment Options

Posted by | Jul 2024

E. David Crawford, MD, Stephen Kaplan, MD, and Kevin T. McVary, MD, FACS, explore the utility of the Optilume® BPH Catheter System, a novel minimally-invasive surgical therapy (MIST). This is the second in a series supported by Laborie.

Dr. McVary begins with an overview of the current BPH market, diagnostic, and treatment algorithms and pharmaceutical/surgical treatment pathways. He illustrates the growing population of men with BPH who are underserved by pharmaceuticals, and those who are concerned about long-term effects of medication on their sexual function. Additionally, he discusses the dangers of delaying surgical management when it is indicated.

Dr. Kaplan then compares the function and outcomes of the Optilume® BPH Catheter System to those of current MIST and invasive surgeries. With an emphasis on the preservation of sexual function and low intraoperative risk, Dr. Kaplan and Dr. McVary discuss the clinical data, their experience with using the Optilume® BPH Catheter System, and their expectations for real-world data.

To see the Thought Leader Q&A session on this topic, click here [link to Q+A on GRU]. To see the first part of this series, click here. For more informational content on the latest developments on men’s health topics like BPH, please visit our Men’s Health Next-Generation Learning Center.

Read More
Optilume® BPH Catheter System: Optilume® Care Pathway and Treatment Options – Q&A Session

Optilume® BPH Catheter System: Optilume® Care Pathway and Treatment Options – Q&A Session

Posted by | Jul 2024

E. David Crawford, MD, Stephen Kaplan, MD, and Kevin T. McVary, MD, FACS, continue their discussion of the utility of the Optilume® BPH Catheter System in this Q&A session.  

To see the main discussion on this topic, click here. This is the second in a series supported by Laborie. To see the first part of this series, click here. For more informational content on the latest developments on men’s health topics like BPH, please visit our Men’s Health Next-Generation Learning Center.

Read More
Optilume® BPH Catheter System: Optilume® BPH Product and Clinical Data Overview

Optilume® BPH Catheter System: Optilume® BPH Product and Clinical Data Overview

Posted by | Jun 2024

E. David Crawford, MD, sits down with Dean S. Elterman, MD, MSC, FRCSC, and Stephen Kaplan, MD, to discuss the evolution of BPH treatment and the Optilume® BPH Catheter System, a novel minimally-invasive surgical therapy (MIST). This is the first in a series supported by Laborie.

Dr. Elterman begins with an overview of the Optilume® BPH Drug Coated Balloon Catheter. He presents the components of the system and their utility. He presents a demonstration of the system in action.

Dr. Kaplan presents data from the clinical investigations of the effectiveness of the Optilume® BPH Catheter System. He provides an overview of the results from the EVEREST study and the landmark PINNACLE trial, which was published in the September 2023 issue of the Journal of Urology. He notes that the major benefits of the treatment include significant flow rate improvement despite the lack of tissue removal and low surgical retreatment rates.

Read More
Optilume® BPH Catheter System Data from the PINNACLE Trial Published in the September 2023 Journal of Urology

Optilume® BPH Catheter System Data from the PINNACLE Trial Published in the September 2023 Journal of Urology

Posted by | Oct 2023

Steven A. Kaplan, MD, joins E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology, to discuss the results of the PINNACLE trial published in the September 2023 issue of the Journal of Urology. The PINNACLE trial was a Phase 3 study examining the effectiveness of treating benign prostate hyperplasia (BPH) with the Optilume® BPH Catheter System.

The Optilume® BPH Catheter System is a novel drug/device combination minimally invasive surgical therapy for the treatment of lower urinary tract symptoms secondary to BPH, and it has been recently approved by the FDA. Dr. Kaplan explains how the mechanical dilation with Optilume® BPH achieves an anterior commissurotomy separating the lateral lobes of the prostate, while delivery of paclitaxel is intended to maintain luminal patency during healing.

Over the course of the discussion, Drs. Kaplan and Crawford examine:

The history of devices used to treat BPH.
The design of the Optilume® BPH Catheter System and its effects on flow and proliferative rates.
The design of the PINNACLE trial.
The immediate and long-term results for patients treated with Optilume® BPH versus those of patients treated with the sham.
What the results may mean for the future of BPH treatment in office and ambulatory settings.
For more informational content on the latest developments on men’s health topics like BPH, please visit our Men’s Health Next-Generation Learning Center.

Read More
  • 1
  • 2

Join the GRU Community

- Why Join? -